The United States is facing a critical moment in its pharmaceutical supply chain — one that has far-reaching implications for healthcare access, patient safety, and national security. A recent Senate Aging Committee hearing shined a spotlight on a growing concern: the federal government’s dependence on foreign-made medications, and the risks this poses to both American patients and domestic manufacturers.

As a U.S.-based pharmaceutical distributor and advocate for domestic production, The DaVinci Company stands firmly behind the movement to rebuild and reinforce America’s pharmaceutical independence.

Read the full article here: Senate Aging Committee Examines Loopholes Endangering American Patients

The Senate’s Message: It’s Time to Buy American

During the hearing, lawmakers voiced serious concerns about the VA’s procurement practices, citing “loopholes” that allow critical medications and active ingredients to be sourced overseas, often from regions vulnerable to disruption.

These dependencies have already shown their fragility — from COVID-era shortages to delays caused by geopolitical tensions and shipping breakdowns. The Committee called for stronger oversight, transparent sourcing, and prioritization of U.S.-manufactured products in federal purchasing.

This conversation hits close to home for those of us in the industry. At TDC, we’ve seen firsthand how reliance on foreign manufacturing can lead to supply disruptions, fluctuating costs, and inconsistencies that ultimately affect patient care.

The DaVinci Perspective: Real Solutions Through U.S. Manufacturing

For The DaVinci Company, “Buy American” isn’t a slogan — it’s a strategy.
Through our partnership with Oxford Pharmaceuticals, we are actively working to expand the footprint of FDA-approved, American-made generics across the VA and Department of Defense healthcare systems.

Our mission aligns directly with what the Senate hearing underscored:

• Security: U.S.-based manufacturing reduces national dependence on volatile international supply chains.
• Safety: Domestic production ensures full compliance with FDA and DEA oversight, maintaining high standards of quality.
• Sustainability: Investing in American manufacturing creates jobs, builds infrastructure, and keeps taxpayer dollars in the U.S. economy.

The article highlighted how the VA’s current procurement loopholes often exclude small and mid-sized American companies that could easily meet the nation’s needs — if only given a fair opportunity to compete.
At TDC, we’re stepping up to that challenge by offering the lowest federal contract prices (TPRs) on key products through January 2026, and by urging CMOPs and federal buyers to add our NDCs to their stocking lists.

A Call for Action in Federal Procurement

This is more than a marketing opportunity — it’s a call to action for the entire healthcare system. The federal government’s purchasing power can directly influence whether essential medicines are made here at home or imported from abroad.

By prioritizing American-made pharmaceuticals in procurement policies, agencies like the VA and DoD can:

• Strengthen the domestic drug supply chain.
• Ensure readiness in times of crisis or global disruption.
• Support the American workforce and innovation ecosystem.

We echo the Senate’s message: now is the time to make procurement reflect patriotism in practice — to invest in American-made medicines for America’s patients.

Looking Ahead: JFPS and Beyond

Next on the horizon, The DaVinci Company will proudly represent our partners at the Joint Federal Pharmacy Seminar (JFPS) this November. Our presence there will provide an opportunity to showcase our expanded product lineup and reaffirm our position as a trusted American supplier for the VA and DoD systems.

Learn more about the upcoming JFPS meeting here: JFPS 2025 Schedule

Our Commitment

At The DaVinci Company, we believe that every tablet produced in America represents not just quality and safety, but economic strength, jobs, and national security. Through continued collaboration with our manufacturing partners and ongoing advocacy for domestic sourcing, we aim to increase access, improve awareness, and deliver value across the healthcare system.

We invite all buyers, partners, and policymakers to join us in supporting American-made pharmaceuticals — protecting patients, promoting transparency, and powering our national recovery.

Read more and explore our full product catalog: Shop Now